Bristol Myers Squibb is paying BioNTech $3.5 billion to board the PD-1/L1xVEGF-A bandwagon. The deal, which features up to $7 ...

Regeneron isn’t the only Big Pharma to spot potential in Hansoh’s obesity pipeline. Merck & Co. ended last year paying $112 ...

Be successful developing Internet of Healthcare Things with realtime medical device data integration. Learn more.

Radiopharmaceuticals are transforming modern medicine, while simultaneously intensifying the pressures on pharmaceutical ...

| When clinical trial steps are managed separately, the study suffers from compounded delays. Discover proven solutions from ...

Discover how Bayer and BlueRock are redefining biotech partnerships. From breakthrough Parkinson’s therapies to a unique “arm ...

Actuate Therapeutics has set its sights on getting elraglusib approved for pancreatic cancer after the glycogen synthase ...

Johnson & Johnson has shared more data on its multifront attack on KLK2, linking a bispecific antibody to 7.9 months ...

Despite being more likely to be diagnosed with triple negative breast cancer (TNBC), Black women remain underrepresented in ...

After Bicara reported a 12-month OS of 61% for its HPV-negative population last week, biotech Merus shared that its ...

Kite Pharma’s bicistronic CAR T-cell therapy hit the main goal of a phase 1a trial, with zero dose-limiting toxicities (DLTs) ...

Immatics’ cell therapy has been linked to a 56% objective response rate (ORR) among 32 heavily pretreated patients with ...